openPR Logo
Press release

Patent Expiry of Key Insulin Brands to Fuel Growth of Biosimilar Insulin

02-27-2013 01:59 PM CET | Health & Medicine

Press release from: RNCOS E-Services Pvt. Ltd.

/ PR Agency: RNCOS E-Services Pvt. Ltd.
Rising prevalence of diabetes in price sensitive markets of India and China to be the driving force behind increased sales of bios

Rising prevalence of diabetes in price sensitive markets of India and China to be the driving force behind increased sales of bios

According to a new research report by RNCOS entitled, “Global Biosimilars Market Forecast to 2015”, biosimilar insulins have a very promising market in the future as the rising incidences of diabetes would require more affordable biosimilar insulins. Both the US and Europe are expected to show a promising growth, but especially significant growth will be exhibited in the developing countries, such as China and India which have the highest diabetes prevalence in the world. These geographies are rapidly adopting the technological advancements related to insulin that are expected to govern maximum growth in this segment. Moreover, patents on some of the rapid-acting or regular insulin analogs have already expired in the US and Europe, with several patent expiries lined up post-2012. Eli Lilly’s Humalog (Insulin Lispro) is expected to be the first drug to face biosimilar competition in 2013.

Besides, our research has found that although being at a nascent stage, the global biosimilar industry holds a huge potential. A number of patent expiries of key biologics and alarmingly rising healthcare and biologic costs across the world are the prime factors triggering the growth of biosimilars. As biosimilars target specific diseases as efficiently as the branded counterparts at a much lesser price, their market seems to hold a much larger pie in the market. The second-generation biosimilars also seems to hold huge potential and is expected to open up new avenues of growth in the global Biosimilars Industry.

The report, by RNCOS, spread in around 140 pages provides an extensive research and in-depth analysis of the current size and future outlook of the Global Biosimilars Market. It provides market analysis of the Biosimilars Industry along with key market segments and geographical segmentation. Various types of biosimilars, such as erythropoietin, human growth hormone, G-CSF, monoclonal antibody, human insulin, and interferons have been analyzed comprehensively in the report. The Biosimilars Industry is quiet diverse in terms of regulated and unregulated markets. Some of the key geographies in this diverse market have been analyzed while compiling the report. A detailed competitive evaluation provides the reader with a comprehensive analysis on the latest industry activities. Overall, the report provides a holistic understanding of the global Biosimilars Industry and its promising future to the reader.

For FREE SAMPLE of this report visit:

Some of our Related Reports are:

- Global Biotech API Market Analysis (
- EPO Biosimilars Market Forecast to 2015 (
- G-CSF Biosimilars Market Forecast to 2015 (
- HGH Biosimilars Market Forecast to 2015 (
- Global Protein Therapeutics Market Forecast to 2015 (

Check Related REPORTS on:


RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

B-129, Sector 6 Noida - 201301

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Patent Expiry of Key Insulin Brands to Fuel Growth of Biosimilar Insulin here

News-ID: 253140 • Views: 2838

More Releases from RNCOS E-Services Pvt. Ltd.

Malaysia Convenience Store Witnessing Tremendous Growth
“Rapid expansion plans of major convenience stores in Malaysia such as 7-Eleve and 99 Speed Mart are expected to drive the market.” says RNCOS Malaysia Convenience store has been witnessing a tremendous growth in the retail industry. Key players in the country are widening their foot prints in retail industry by innovatively increasing the product portfolio as per the consumer behavior and increasing the number of stores. There is a cut
Growing Opportunity in the Global Enterprise Software Market
“Increasing adoption of enterprise resource management software, customer relationship management software and human resource management software is expected to drive the Global Enterprise Software market.” Says RNCOS The global enterprise software market has reported a significant growth in the recent years and is presenting ample opportunities to the industry’s players. With increasing global competition and rising awareness regarding enterprises software across the globe, the worldwide enterprise software market is poised to
Global Wearable Medical Device Market Outlook 2020
By wearable medical devices we understand non-invasive, autonomous health tools, which aid in clinical monitoring beyond the hospitals. The application of wearable ranges from monitoring glucose levels in blood to managing chronic diseases such as heart diseases, asthma and diabetes. These devices generally provide non-invasive sensing, local processing, user feedback, and communication capabilities. In the latest report “Global Wearable Medical Device Market Outlook 2020”, RNCOS’ analysts have endeavored to
Global Point-of-Care Diagnostics Market Outlook 2020
It is widely accepted that disease prevention and risk-reduction strategies have the potential to lower disease burden as well as improve the overall health of individuals. POCT technology offers such potential for diagnosis and treatment of patients, as it facilitates rapid availability of test results and hence, early clinical decision making and intervention. Amidst a rising disease incidence, reduced budget, growing focus towards personalization of care, and ever-increasing integration of

All 5 Releases

More Releases for Biosimilars

Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on